• About WordPress
    • WordPress.org
    • Documentation
    • Learn WordPress
    • Support
    • Feedback
  • Log In
  • Request Membership
Skip to content
Medxy AI
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • MedXY story
  • 用户
  • 登录
  • 注册
  • 会员
  • 注销
  • 账号
  • 密码重置
  • Wellness & Lifestyle
  • Clinical Updates
  • Medical News
  • MedXY story
  • 用户
  • 登录
  • 注册
  • 会员
  • 注销
  • 账号
  • 密码重置
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • tirzepatide
Semaglutide and Tirzepatide Significantly Reduce Hospitalization and Mortality in Cardiometabolic HFpEF Patients: Real-World Evidence
Posted inClinical Updates Wellness & Lifestyle

Semaglutide and Tirzepatide Significantly Reduce Hospitalization and Mortality in Cardiometabolic HFpEF Patients: Real-World Evidence

Posted by By MedXY 08/31/2025
Real-world analysis shows semaglutide and tirzepatide reduce hospitalization for heart failure or all-cause mortality by over 40% in patients with cardiometabolic HFpEF, with no significant difference between the two drug options.
Read More
Tirzepatide Enhances Quality of Life in Adults with Obesity or Overweight: Insights from the SURMOUNT-3 Trial
Posted inClinical Updates Wellness & Lifestyle

Tirzepatide Enhances Quality of Life in Adults with Obesity or Overweight: Insights from the SURMOUNT-3 Trial

Posted by By MedXY 08/30/2025
Tirzepatide significantly improves health-related quality of life alongside weight reduction in adults with obesity or overweight, especially those experiencing physical function limitations, according to SURMOUNT-3 trial results.
Read More
Tirzepatide Significantly Lowers Predicted 10-Year Type 2 Diabetes Risk in Chinese Adults with Overweight or Obesity: Insights from the SURMOUNT-CN Trial
Posted inClinical Updates Wellness & Lifestyle

Tirzepatide Significantly Lowers Predicted 10-Year Type 2 Diabetes Risk in Chinese Adults with Overweight or Obesity: Insights from the SURMOUNT-CN Trial

Posted by By MedXY 08/30/2025
Post hoc analysis of the SURMOUNT-CN trial shows tirzepatide markedly reduces the 10-year predicted risk of type 2 diabetes in Chinese individuals with overweight or obesity, regardless of baseline BMI or prediabetes status.
Read More
Tirzepatide’s Role in Obesity-Related HFpEF: Influence of BMI, Central Adiposity, and Weight Loss from the SUMMIT Trial
Posted inClinical Updates Wellness & Lifestyle

Tirzepatide’s Role in Obesity-Related HFpEF: Influence of BMI, Central Adiposity, and Weight Loss from the SUMMIT Trial

Posted by By MedXY 08/17/2025
Tirzepatide reduces heart failure risk in obese HFpEF patients regardless of BMI or central adiposity, with greater benefits on exercise capacity and symptom scores associated with higher BMI and weight loss.
Read More
Enhanced Weight Loss for Menopausal Women: The Role of Tirzepatide and Hormone Therapy
Posted inWellness & Lifestyle

Enhanced Weight Loss for Menopausal Women: The Role of Tirzepatide and Hormone Therapy

Posted by By MedXY 07/29/2025
A new study reveals combining tirzepatide and hormone therapy significantly boosts weight loss in postmenopausal women, offering a promising approach to managing obesity-related health risks.
Read More
Posted inWellness & Lifestyle

The End of the Diet? Inside the Game-Changing Anti-Obesity Drug Revolution

Posted by By MedXY 07/25/2025
New anti-obesity medications are transforming weight management, challenging old paradigms, and raising new questions about the future of dieting and health.
Read More
  • Enhancing Metformin Efficacy and Tolerability in Prediabetes Through a Fermentable Carbohydrate-Rich Diet
  • Unlocking Precision Nutrition: Genetic Insights from the MIND Diet Trial for Cognitive Health
  • Long-Term Outcomes of the DASH Intervention in Nonobstructive Coronary Artery Disease: Follow-Up of the DISCO-CT Study
  • Dose-Dependent Enhancement of L-Tryptophan-Induced Gut Hormone Secretion and Appetite Suppression by Intraduodenal Calcium in Obesity
  • Decoding Metabolic Adaptation: Caloric Restriction’s Impact on Organ Size in the CALERIE 2 Trial
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging AI Alzheimer's disease artificial intelligence atrial fibrillation blood pressure breast cancer cardiovascular health cardiovascular risk clinical trial COVID-19 diabetes diet dinh dưỡng exercise GLP-1 health heart failure HFpEF Hypertension immunotherapy longevity mental health metformin Mortality NAFLD nutrition obesity Pregnancy prevention public health randomized controlled trial randomized trial semaglutide sexual health Suy Tim sức khỏe tim mạch TAVI thử nghiệm lâm sàng Trí tuệ nhân tạo type 2 diabetes weight loss wellness women's health 心力衰竭

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top